XOMA Corporation is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.
XOMA's scientific research produced a portfolio of six endocrine assets, each of which has the opportunity to address multiple indications. Two of the assets were developed through the XMet platform, which consists of separate classes of Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of metabolic disorders.
XOMA is also developing gevokizumab, an interleukin-1β (IL-1β) modulating antibody. XOMA is conducting a Phase 3 program in pyoderma gangrenosum, a rare ulcerative skin disease, and is implementing blinded futility analyses into the Phase 3 clinical program to allow informed go/no go decisions.
In addition, the Company is exploring strategic alternatives for its manufacturing facilities and its biodefense programs. XOMA 3AB, an antibody candidate in preclinical development to neutralize the botulinum toxin, among the most deadly bioterrorism threats, is under development through funding provided by the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
XOMA is located in Berkeley, California.
Nov 12, 2015
XOMA to Present at Two Upcoming Investor Conferences
Dec 1, 2015 at 10:00 AM ET
27th Annual Piper Jaffray Healthcare Conference
Nov 19, 2015 at 7:20 AM PT
Jefferies Autumn 2015 Global Healthcare Conference London